The Ministry of Health and Family Welfare has formally added the widely used nerve-pain drug Pregabalin to Schedule H1 of the Drugs Rules, 1945 — a category reserved for substances with high abuse potential. The Government of India has officially…
Central Drugs Standard Control Organisation (CDSCO) in its latest notification has moved to tighten oversight of the booming cosmetics industry in India, issuing unambiguous guidance on what constitutes a cosmetic product, how it may lawfully be used, and what actions…
The Central Drugs Standard Control Organization (CDSCO), operating under the Directorate General of Health Services, Government of India, has issued a sweeping directive to all State and Union Territory Drug Controllers, calling for urgent and coordinated enforcement action against the…
📌 Introduction In today’s rapidly evolving pharmaceutical landscape, staying updated with drug approvals, regulatory changes, and compliance requirements is no longer optional—it’s critical. Yet, professionals across the industry—regulatory experts, manufacturers, consultants, and marketers—face a common challenge: 👉 Fragmented information spread…
Recent Post
- India brings Pregabalin under Schedule H1
- CDSCO Issues Stern Warning Against Injectable Cosmetics and Misleading Beauty Claims
- CDSCO Orders Nationwide Crackdown on Unauthorised GLP-1 Weight Loss Drugs
- Drug Applications with Unanswered Queries to Be Rejected Within 30 Days by CDSCO
- ⚖️ “No Approval, No Market”: Delhi High Court Sends a Strong Message on Unapproved Drugs & FDCs
